GlassScriptPhysician profile
Catherine L Eden
NPI 1215226865
$4,427.60
in general payments reported to CMS, 2019-2025
36 companies · $589 in 2025
The $589 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $176 · 2021: $129 · 2022: $572 · 2023: $859 · 2024: $1,848 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471 · Travel and Lodging: $789 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.38 |
| Travel and Lodging | $789.49 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,089.52 | 2019-2025 | Solyx Sis System, Ams 800 Artificial Urinary Sphincter, Lithovue |
| Dendreon Pharmaceuticals LLC | $522.86 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $354.44 | 2023-2024 | Gemtesa, Orgovyx |
| Myriad Genetic Laboratories, INC. | $303.47 | 2023-2024 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $273.29 | 2020-2025 | |
| Astellas Pharma US INC | $214.09 | 2019-2024 | Xtandi |
| Abbvie INC. | $179.38 | 2021-2025 | Lupron Depot |
| Astrazeneca Pharmaceuticals LP | $150.87 | 2022-2025 | Lynparza, Imfinzi |
| Janssen Biotech, INC. | $140.18 | 2022-2025 | Erleada, Akeega, Balversa |
| Verity Pharmaceuticals INC. | $128.22 | 2022-2023 | Trelstar |
| Myovant Sciences INC. | $117.22 | 2022 | |
| Olympus America INC. | $90.01 | 2022-2025 | Itind System |
| Merck Sharp & Dohme LLC | $83.62 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Teleflex LLC | $76.01 | 2022-2024 | Urolift |
| Tempus Ai, INC | $66.86 | 2024-2025 | Xt Cdx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $62.73 | 2023 | |
| Travere Therapeutics, INC. | $62.09 | 2019-2020 | |
| Rochester Medical Corporation | $61.22 | 2022 | |
| Angiodynamics, INC. | $48.74 | 2022 | |
| Urogen Pharma, INC. | $39.91 | 2025 | |
| Genzyme Corporation | $33.61 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $33.27 | 2024 | Xiaflex, Aveed |
| Coloplast Corp | $32.67 | 2022 | |
| Bard Access Systems, INC. | $31.17 | 2019 | |
| Valencia Technologies Corporation | $30.22 | 2025 | Ecoin Device Kit |
| Medtronic, INC. | $25.15 | 2023 | Interstim |
| Tolmar Pharmaceuticals, INC. | $23.99 | 2022 | |
| Progenics Pharmaceuticals, INC. | $22.68 | 2025 | |
| Pfizer INC. | $20.94 | 2025 | |
| Immunitybio, INC. | $18.58 | 2025 | |
| 180 Medical, INC. | $18.54 | 2019 | |
| Accord Healthcare, INC. | $17.52 | 2024 | |
| Endo USA, INC. | $17.16 | 2024 | Xiaflex |
| Telix Pharmaceuticals | $13.47 | 2023 | Illuccix |
| Neotract INC. | $12.47 | 2020 | |
| Convatec INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Eden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.